

**Supplementary Table S1:** overview of previously published 2D iPSC-CM cardiac arrhythmia disease models

Syndrome	Causal gene	Experimental approach	Cellular phenotype	Ref
LQTS	<i>KCNQ1</i> (c.1893del)	PC, MEA	Reduced $I_{Kr}$ , prolonged APD, reduced wild-type <i>KCNQ1</i> mRNA and protein	[102]
	<i>KCNQ1</i> exon 7 deletion	PC	Reduced $I_{Ks}$ , APD prolongation, reduced wild type <i>KCNQ1</i> mRNA and protein, small molecule ML277 partially restored APD and reversed the decreased $I_{Ks}$ .	[103]
	<i>KCNQ1</i> p.(Arg594Gln) p.(Arg190Gln)	PC, MEA	Prolonged APD, reduced $I_{Ks}$ activation that was reversed by hERG allosteric modulator LUF7346	[104]
	<i>KCNH2</i> p.(Ala614Val)	PC	Prolonged APD, reduction of $I_{Kr}$ , EADs, arrhythmias and potential improvement with pinacidil	[105]
	<i>KCNH2</i> p.(Arg176Trp)	PC, MEA	Prolonged APD, reduced $I_{Kr}$ , demonstrated arrhythmogenic electrical activity	[106]
	<i>KCNH2</i> p.(Gly1681Ala)	PC	APD prolongation and EADs	[92]
	<i>KCNH2</i> p.(Asn996Ile)	PC, MEA	Prolonged APD, reduced $I_{Kr}$ activation that was reversed by hERG allosteric modulator LUF7346	[104]
	<i>SCN5A</i> p.(Phe1473Cys)	PC	Delayed repolarization, prolonged QT interval with increase in pacing improving the phenotype, increased risk of fatal arrhythmia	[107]
	<i>SCN5A</i> p.(Val1763Met)	PC	Prolonged APD, elevated late $I_{Na}$ current, Nav1.5 blocker can reverse related symptom	[108]
	<i>SCN5A</i> p.(Val240Met) p.(Arg535Gln)	PC	Insignificant increase in APD, delayed time to peak $I_{Na}$ inactivation	[109]
	<i>SCN5A</i> p.(Arg1644His)	PC, MEA	Prolonged APD, high EADs, and accelerated recovery from inactivation of $Na^+$ currents. Rescue of abnormal phenotype by mexiletine and ranolazine	[103]

Syndrome	Causal gene	Experimental approach	Cellular phenotype	Ref
	<i>KCNJ2</i> p.(Arg218Trp) p.(Arg67Trp) p.(Arg218Gln)	MEA, CI	Strong arrhythmic events, higher incidence of irregular Ca <sup>2+</sup> release. Flecainide, but not pilsicainide, suppressed irregular Ca <sup>2+</sup> release and arrhythmic events	[111]
	<i>CACNA1C</i> p.(Gly1216Ala)	PC, CI	APD prolongation and DADs, abnormal calcium handling, irregular and slow contraction. Roscovitine rescued abnormal cellular phenotype	[112]
	<i>CALM1</i> p.(Phe142Leu)	PC, MEA, CI	Prolonged APD, defective I <sub>Ca-L</sub> inactivation, altered rate-dependency and response to isoproterenol. Repolarization abnormalities reversed by verapamil	[113]
	<i>CALM2</i> p.(Asn98Ser)	PC	Lower beating rate, prolonged APD, and impaired I <sub>Ca-L</sub> inactivation, correction of the mutant allele rescued abnormal phenotype	[114]
	<i>CALM2</i> p.(Asp130Gly)	PC, IF	Prolonged APD, disrupted Ca <sup>2+</sup> cycling properties, and diminished Ca <sup>2+</sup> /CaM-dependent inactivation of I <sub>Ca-L</sub> . Suppressing the mutant gene rescued abnormal phenotype	[115]
	<i>PKP2</i> (c.2484C>T)	PA, MEA, CI	Reduced I <sub>Na</sub> , deficit restored by transfection of WT gene	[116]
	<i>PKP2</i> p.(Arg101His)	PC	Reduced APD90	[84]
BrS	<i>RRAD</i> p.(Arg211His)	PC, CI	Reduced V <sub>max</sub> of AP, prolonged APs and increased incidence of EADs, decreased I <sub>Na</sub> peak amplitude, increased I <sub>Na</sub> persistent amplitude, decreased I <sub>Ca-L</sub> amplitude	[117]
	<i>SCN5A</i> p.(Arg1638X) p.(Trp156X)	PC	Reduced V <sub>max</sub> , reduced I <sub>Na</sub>	[118]
	<i>SCN5A</i> p.(Ala226Val)+ p.(Arg1629X) <i>SCN5A</i>	PC	Ala226Val/Arg1629X: Reduced I <sub>Na</sub> , reduced V <sub>max</sub> and APA Thr1620Met: no effect on I <sub>Na</sub> and normal AP	[119]

Syndrome	Causal gene	Experimental approach	Cellular phenotype	Ref
	p.(Thr1620Met)			
	<i>SCN5A</i> p.(Arg367His)	PC	Reduced $I_{Na}$ , shift in activation and inactivation voltage-dependence curves, faster recovery from inactivation	[120]
	<i>SCN5A</i> p.(Ala735Val)	PC	Reduced APA and $V_{max}$ , reduced $I_{Na}$ , shift in activation and inactivation voltage-dependence curves	[121]
	<i>SCN10A</i> p.(Arg1250Gln)+ p.(Arg1268Gln)	PC, CI	Reduced peak $I_{Na}$ and $I_{NaL}$ , accelerated recovery from inactivation in patient iPSC-CMs, reduced $I_{Ca-L}$ and $I_{Ks}$ , reduced APA and $V_{max}$ , increased EAD-like events	[85]
	<i>SCN1B</i> p.(Leu210Pro)+ p.(Pro213Thr)	PC, CI	Reduced peak $I_{Na}$ and $I_{NaL}$ , positive shift in the voltage dependence of activation and negative shift of the inactivation, reduction in $I_{Ks}$ and $I_{Kr}$ , Reduced APA and $V_{max}$ , increased arrhythmia like events	[86]
CPVT	<i>RYR2</i> p.(Ser406Leu)	PC, CI	Elevated diastolic $Ca^{2+}$ concentrations, a reduced SR $Ca^{2+}$ content, DADs and arrhythmia, dantrolene can restore these phenotype	[122]
	<i>RYR2</i> p.(Pro2328Ser)	PC, CI	Increased non-alternating variability of $Ca^{2+}$ transients in response to isoproterenol and $\beta$ -agonists decreased AP upslope velocity	[122]
	<i>RYR2</i> p.(Met4109Arg)	PC, MEA, CI	DADs were eliminated by flecainide and thapsigargin	[123]
	<i>RYR2</i> p.(Leu3741Pro)	CI, MEA	Altered intracellular $Ca^{2+}$ homeostasis, $\beta$ -adrenergic stimulation potentiated spontaneous $Ca^{2+}$ waves and prolonged $Ca^{2+}$ sparks. Flecainide ameliorated disease phenotype	[124]
	<i>RYR2</i> p.(Ile4587Val)	PC, CI	Increased diastolic $Ca^{2+}$ waves and DADs with pacing, while S107 suppressed the DADs	[126]

Syndrome	Causal gene	Experimental approach	Cellular phenotype	Ref
	<i>CASQ2</i> p.(Asp307His)	PC, CI	$\beta$ -adrenergic agonist caused DADs, oscillatory arrhythmic pre-potentials, and diastolic $[Ca^{2+}]_i$ rise	[35,126]
	<i>CASQ2</i> p.(Asp307His)	PC, CI	$Ca^{2+}$ transient irregularities, EADs, and reduced threshold for store overload-induced $Ca^{2+}$ release, $\beta$ -blockers prevented arrhythmia	[127]
ACM	<i>PKP2</i> (c.2484C>T) <i>PKP2</i> (c.2013delC)	CI, seahorse metabolic assay	Abnormal plakoglobin nuclear translocation, decreased $\beta$ -catenin activity, exaggerated lipogenesis and apoptosis calcium-handling deficits	[128]

Adapted and updated from Garg et al. (2018) and Pan et al. (2021) [9,10]. PC: patch clamp; IF: immunofluorescence; MEA: Multi electrode array; WB: Western Blot; CI: Calcium imaging; AFM: atomic force microscopy; AP: action potential;  $I_{Ks}$ : slow delayed rectifier  $K^+$  current; ER: endoplasmic reticulum; APD50-90: Action potential duration at 50%–90% of repolarisation; EAD: early after depolarisation;  $I_{Kr}$ : rapid delayed rectifier  $K^+$  current;  $I_{Ca-L}$ : L-type calcium current; APA: action potential amplitude;  $V_{max}$ : maximum rate of rise of the action potential;  $I_{Na}$ : sodium current; DAD: delayed after repolarisation; FP: field potential; CV: conduction velocity;  $I_{to}$ : transient outward current; SR: sarcoplasmic reticulum; EM: electron microscope.